SciELO - Scientific Electronic Library Online

vol.29 issue2Complications of surgery after radiotherapy and adjuvant chemotherapy in non-small cell lung cancer: Analysis of a series of 16 patients author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Oncología (Barcelona)

Print version ISSN 0378-4835


COBO DOLS, M. et al. New prospects in non-small cell lung cancer treatment: pharmacogenomics. Oncología (Barc.) [online]. 2006, vol.29, n.2, pp.13-22. ISSN 0378-4835.

The most commonly used chemotherapy strategy in advanced non-small cell lung cancer (NSCLC) today is the combination of two drugs, mainly cisplatin with another drug (gemcitabine, vinorelbine, taxanes, irinotecan). In the last decade attempts have been made to overcome chemotherapy resistance without benefit in outcome. There is a "plateau" in the results which seems unable to progress beyond the frontier of 8-10 months of median survival. At present, research in cancer survival is focused on translational pharmacogenomics, with the goal of providing individualized CT based on different genetic traits, such a polymorphisms, gen mutation and overexpresion of drug target gene transcripts, and several molecular assays can been used to tailor chemotherapy in the care of lung cancer patients. Accumulated evidence indicates that many genetic markers are related to chemotherapy resistance. One of the most important goals in translational research is to investigate the clinical use of the DNA repair pathways. Several genes such as ERCC1, XPD polymorphisms. RRM1, BCRA1, etc are related to cisplatin and other drugs resistance.

Keywords : Non-small cell lung cancer; Chemotherapy; Pharmacogenomics.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License